



18 letters^{1,2*}

Imagine what your dry AMD patients could really gain

*Approximate ETDRS letter gain calculated from mean post-operative CDVA (logMAR) improvement

AMD, age-related macular degeneration; CDVA, corrected distance visual acuity;
LogMAR, logarithm of the minimum angle of resolution.

 **SharpView**
Ophthalmology

In patients with dry AMD and cataracts, a standard monofocal IOL only addresses half their problem^{2,4,5}

- Standard monofocal IOLs provide modest visual acuity gains of ~7 letters^{6*} but do not address central vision loss or account for changes in fixation^{2,4,5}

Central scotoma and distortion†



Sharp image with less blur†



Simulated post-operative visual distortion

- EyeMax Mono delivers mean visual acuity gains of 18 ETDRS letters,^{2†} more than double that previously reported with standard cataract surgery^{2,6}

*Mean gain in ETDRS letters at a mean post-operative follow-up of 7 months⁴


†For illustrative purposes only. Degree of visual impairment and post procedure results will vary

*Approximate ETDRS letter gain calculated from mean post-operative CDVA (logMAR) improvement

ETDRS, early treatment diabetic retinopathy study; IOL, intraocular lens; GA, geographic atrophy; LogMAR, logarithm of the minimum angle of resolution.

EyeMax Mono is uniquely shaped to deliver an optimised image to all areas of the macula up to 10° from the fovea centre¹⁻³

- To compensate for macular function loss, in some patients fixation may shift to a healthier part of the macula and a preferred retinal locus (PRL*) may naturally form⁷
- Working with this natural adaption process, EyeMax Mono utilises transverse asphericity to extend the breadth of focus to deliver a sharper image to this naturally formed PRL¹⁻³




Simulated retinal images
are for illustrative purposes only
*PRL may also be known as eccentric fixation
GA, geographic atrophy.

EyeMax Mono
image at 10°




Standard monofocal
IOL image at 10°



**EyeMax Mono is
designed to work with
a naturally formed PRL**

EyeMax Mono significantly improves visual acuity¹⁻³

- Advanced AMD patients (N=244 eyes) achieved mean gains of 3+ lines post-implantation (ETDRS gain of 18 letters)^{2*}



Comparable gains were also achieved for corrected near visual acuity^{2†}

Mean pre-operative CDVA (logMAR) improved from 1.06 to 0.71 post-operatively (CI -0.39 to -0.32; $p < 0.0001$). Error bars represent SEM

EyeMax Mono can improve reading function in patients with dry AMD¹

- Mean reading speed improved by 57%¹
 - Increase from 28 ± 19 wpm pre-operatively to 44 ± 31 wpm post-operatively (n=7)
- Reading acuity[‡] and critical print size[§] also improved following EyeMax Mono implantation¹

*Comparing pre- and post-operative assessments.^{1,2} Mean follow up at 3-months. Mean age at surgery 80 years. Baseline LogMAR visual acuity ≥ 0.3 ²

†Mean pre-operative CNVA (logMAR) improved from 1.36 to 0.88 post-operatively (CI -0.53 to -0.44; $p < 0.0001$).

‡1.07 ± 0.31 pre-operatively to 0.9 ± 0.37 post-operatively logMAR (n=7) §1.04 ± 0.25 pre-operatively to 0.95 ± 0.27 post-operatively logMAR (n=7)

CDVA, corrected distance visual acuity; CNVA, corrected near visual acuity; ETDRS, early treatment diabetic retinopathy Study; GA, geographic atrophy; LogMAR, logarithm of the minimum angle of resolution; SEM, standard error of the mean; wpm, words per minute.

EyeMax Mono: A unique optical innovation designed to improve visual acuity and function¹⁻³

Specifically designed for dry AMD patients with central vision loss¹⁻³

- **Foldable, injectable, single-piece IOL**
- **Square-edge design**
- **UV-absorbing, hydrophobic, soft, yellow acrylic**
- **Design accounts for chromatic and spherical aberration**



EyeMax Mono helps you deliver what matters most for your dry AMD patients¹⁻³

- EyeMax Mono uniquely optimises image quality out to 10° from the fovea centre to improve visual function¹⁻³
- EyeMax Mono delivers mean visual acuity gains of 18 ETDRS letters, more than double that previously reported with standard cataract surgery (~7 letters)^{2,6†‡}
- EyeMax Mono improves mean reading speed^{1-3†}
- EyeMax Mono has a safety profile consistent with standard cataract procedures, with no additional training required for the surgeon or rehabilitation for the patient^{1,2,8}

EyeMax Mono should support central vision during disease progression, provided there is healthy macular tissue remaining within 10° of the fovea centre¹⁻³

For more information please speak to your Key Account Manager

*Approximate ETDRS letter gain calculated from mean post-operative CDVA (logMAR) improvement

†Mean gain in ETDRS letters at a mean post-operative follow-up of 7 months⁴

‡Increase from 28 ± 19 wpm pre-operatively to 44 ± 31 wpm post-operatively (n=7)

CDVA, corrected distance visual acuity; ETDRS, early treatment diabetic retinopathy study; logMAR, logarithm of the minimum angle of resolution; wpm, words per minute.

References:

1. Robbie SJ, et al. J Refract Surg 2018;34:718–25. **2.** Qureshi MA, et al. Eur J Ophthalmol 2018;28(2):198–203. **3.** Grzybowski A, et al. Ann Transl Med. 2020;8(22):1549
4. Chakrabarti M, et al. Available at: <https://crstodayeurope.com/articles/2015-mar/iol-selection-for-patients-with-age-related-macular-degeneration/>. Accessed Sep 2021.
5. Venkataraman AP, et al. Biomed Opt Express. 2021;12(6):3082-3090. **6.** Huynh N, et al. Ophthalmology 2014;121:1229–36. **7.** Ramírez Estudillo, JA, et al. Int J Retin Vit. 2017;3(21):1-8. **8.** Badala F, et al. Poster presented at AAO 2018.



2460

EyeMax Mono™ is a registered trademark of Sharpview Ophthalmology Limited
Job Bag number: SHV/EMM/001/a | Date of preparation: Sep 2021

EyeMax Mono is designed to optimise visual outcomes in patients with dry AMD. Please refer to the Instructions For Use. Adverse events should be reported as soon as possible to eventreporting@sharpviewophthalmology.com